Madrigal Pharmaceuticals, Inc. · Transaction Apr 10, 2023 · Filed May 19, 2023 · $1,001 to $15,000
NASDAQ NMS - GLOBAL MARKET · MDGL
-2.38% · -$11.61 · Vol 43.9K
Live · updated 10:52:53 ET
Madrigal Pharmaceuticals Inc
Biotechnology
$476.11
Follow $MDGL
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $MDGL by emailVeridion Score
BETAHIGH CONF · 6 of 6 factors measuredThu Oct 8 · live session · daily score · 2h old · MDGL
MethodologyMDGL
Madrigal Pharmaceuticals Inc
Thu Oct 8 · live session · daily score · 2h old
Middle range
Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
52/ 100
Veridion Score
Middle range · HIGH confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: HIGH · 6 of 6 factors measured · Thu Oct 8 · live session · daily score · 2h old
Veridion Score History · 90D
Loading score history
AI Analysis
SovereignWhy is MDGL moving today?
Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Madrigal Pharmaceuticals Inc
PHARMACEUTICAL PREPARATIONSListed since
2007
Employees
915
Country
US
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
Key statistics
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Open
$486.37
Day high
$492.33
Day low
$476.11
Previous close
$487.72
52W high
$602.83
-21.02% from high
52W low
$412.35
33% of range
Market cap
$11.3B
EPS
$-12.2200
Beta
0.00
Shares out
23.1M
Volume
43.9K
0.19× rel vol
Avg volume
234.4K
VWAP
$483.01
Price history computed in-house
1W
-4.72%
1M
-10.87%
3M
-11.29%
1Y
+8.96%
YTD
-18.24%
SMA 50 $520.12 · below
SMA 200 $509.78 · below
52W position 33%
MDGL overview
Related filings and maps
Public disclosures
Congress activity in MDGL
1 filers · 0 buys · 1 sells (0 labeled S (partial)) · Apr 10, 2023 to Apr 10, 2023 · House 1 / Senate 0
All available history · Latest 1 of 1 lines · Read 2026-10-08T14:53:28.383Z
Official filing ↗
Federal contracts
MDGL contract awards, year to date.
Public federal awards linked to this ticker.
Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for MDGL in this window.
Lobbying spend
MDGL lobbying filings, year to date.
Registered lobbying filings matched to Madrigal Pharmaceuticals Inc.
Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for MDGL in this window.
Analyst ratings
Sovereign unlock shows live analyst consensus for MDGL.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.